OKUR · OnKure Therapeutics, Inc.
The latest filing states the doubt was alleviated.
“As of December 31, 2025, the Company had determined that substantial doubt about the Company's ability to continue as a going concern for a period of at least 12 months from the date of the issuance of those financial statements did exist. However, following completion of the 2026 Private Placement (see Note 9), management believes the Company's cash and cash equivalents will be sufficient to fund its current operating plan for at least the next 12 months from the date of issuance of these consolidated financial statements and as such substantial doubt has been alleviated.”View the 10-Q filed May 5, 2026
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-06-22 | Saccomano Nicholas A |
Director, President and CEO |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan. This transaction was executed in multiple trades at prices ranging from $4.27 to $4.54. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Includes 4,000 shares acquired under the Issuer's 2024 Employee Stock Purchase Plan on May 20, 2026. |
Class A Common Stock
|
86 |
| 2026-06-22 | Leverone Jason A. |
Chief Financial Officer |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan. This transaction was executed in multiple trades at prices ranging from $4.27 to $4.54. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Includes 3,105 shares acquired under the Issuer's 2024 Employee Stock Purchase Plan on May 20, 2026. |
Class A Common Stock
|
303 |
| 2026-06-04 | Phillips Andrew John |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date. |
Stock Option (right to buy)
|
7,650 |
| 2026-06-04 | Ratcliffe Liam |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date. |
Stock Option (right to buy)
|
1,275 |
| 2026-06-04 | GREY MICHAEL G |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date. |
Stock Option (right to buy)
|
7,650 |
| 2026-06-04 | Jansen Valerie Malyvanh |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date. |
Stock Option (right to buy)
|
7,650 |
| 2026-06-04 | Carruthers R Michael |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date. |
Stock Option (right to buy)
|
7,650 |
| 2026-06-04 | Mathers Edward T |
10% Owner |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date. |
Stock Option (right to buy)
|
7,650 |
| 2026-04-01 | Leverone Jason A. |
Chief Financial Officer |
Award↑
Filing footnotes — Employee Stock Option (right to buy) (Direct)
1/48th of the shares subject to the option shall vest on May 1, 2026 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. |
Employee Stock Option (right to buy)
|
110,000 |
| 2026-04-01 | Saccomano Nicholas A |
Director, President and CEO |
Award↑
Filing footnotes — Employee Stock Option (right to buy) (Direct)
1/48th of the shares subject to the option shall vest on May 1, 2026 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. |
Employee Stock Option (right to buy)
|
330,000 |
| 2026-04-01 | Hartley Dylan |
Chief Scientific Officer |
Award↑
Filing footnotes — Employee Stock Option (right to buy) (Direct)
1/48th of the shares subject to the option shall vest on May 1, 2026 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. |
Employee Stock Option (right to buy)
|
110,000 |
| 2026-04-01 | Agresta Samuel |
Chief Medical Officer |
Award↑
Filing footnotes — Employee Stock Option (right to buy) (Direct)
1/48th of the shares subject to the option shall vest on May 1, 2026 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. |
Employee Stock Option (right to buy)
|
110,000 |
| 2026-03-31 | Ratcliffe Liam |
Director |
Other↑
|
No Securities Owned
|
0 |
| 2026-03-31 | Ratcliffe Liam |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
1/36th of the shares subject to the option shall vest on April 30, 2026 and on the last day of each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. |
Stock Option (right to buy)
|
15,300 |
| 2026-03-23 | Leverone Jason A. |
Chief Financial Officer |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan. This transaction was executed in multiple trades at prices ranging from $3.995 to $4.235. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU. |
Class A Common Stock
|
301 |
| 2026-03-23 | Saccomano Nicholas A |
Director, President and CEO |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan. This transaction was executed in multiple trades at prices ranging from $3.995 to $4.235. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU. |
Class A Common Stock
|
86 |
| 2025-12-31 | Mathers Edward T |
10% Owner |
Award↑
Filing footnotes — Class A Common Stock (Direct)
These securities are fully vested restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Class A Common Stock. The RSUs were granted to the Reporting Person in lieu of a quarterly cash retainer, at the election of the Reporting Person, under the Issuer's Outside Director Compensation Policy. |
Class A Common Stock
|
3,911 |
| 2025-12-31 | Manke Isaac |
Director |
Award↑
Filing footnotes — Class A Common Stock (Direct)
These securities are fully vested restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Class A Common Stock. The RSUs were granted to the Reporting Person in lieu of a quarterly cash retainer, at the election of the Reporting Person, under the Issuer's Outside Director Compensation Policy. |
Class A Common Stock
|
5,258 |
| 2025-12-22 | Leverone Jason A. |
Chief Financial Officer |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan. This transaction was executed in multiple trades at prices ranging from $2.82 to $3.04. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Includes 4,000 shares acquired under the Issuer's 2024 Employee Stock Purchase Plan on November 20, 2025. |
Class A Common Stock
|
302 |
| 2025-12-22 | Saccomano Nicholas A |
Director, President and CEO |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan. This transaction was executed in multiple trades at prices ranging from $2.82 to $3.04. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Includes 4,000 shares acquired under the Issuer's 2024 Employee Stock Purchase Plan on November 20, 2025. |
Class A Common Stock
|
87 |
| 2025-09-30 | Mathers Edward T |
10% Owner |
Award↑
Filing footnotes — Class A Common Stock (Direct)
These securities are fully vested restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Class A Common Stock. The RSUs were granted to the Reporting Person in lieu of a quarterly cash retainer, at the election of the Reporting Person, under the Issuer's Outside Director Compensation Policy. |
Class A Common Stock
|
4,125 |
| 2025-09-30 | Manke Isaac |
Director |
Award↑
Filing footnotes — Class A Common Stock (Direct)
These securities are fully vested restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Class A Common Stock. The RSUs were granted to the Reporting Person in lieu of a quarterly cash retainer, at the election of the Reporting Person, under the Issuer's Outside Director Compensation Policy. |
Class A Common Stock
|
5,545 |
| 2025-09-22 | Saccomano Nicholas A |
Director, President and CEO |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan. This transaction was executed in multiple trades at prices ranging from $2.60 to $2.645. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU. |
Class A Common Stock
|
88 |
| 2025-09-22 | Leverone Jason A. |
Chief Financial Officer |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan. This transaction was executed in multiple trades at prices ranging from $2.60 to $2.645. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU. |
Class A Common Stock
|
303 |
| 2025-06-30 | Manke Isaac |
Director |
Award↑
Filing footnotes — Class A Common Stock (Direct)
These securities are fully vested restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Class A Common Stock. The RSUs were granted to the Reporting Person in lieu of a quarterly cash retainer, at the election of the Reporting Person, under the Issuer's Outside Director Compensation Policy. |
Class A Common Stock
|
6,311 |
| 2025-06-30 | Mathers Edward T |
10% Owner |
Award↑
Filing footnotes — Class A Common Stock (Direct)
These securities are fully vested restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Class A Common Stock. The RSUs were granted to the Reporting Person in lieu of a quarterly cash retainer, at the election of the Reporting Person, under the Issuer's Outside Director Compensation Policy. |
Class A Common Stock
|
4,694 |
| 2025-06-23 | Saccomano Nicholas A |
Director, President and CEO |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan. This transaction was executed in multiple trades at prices ranging from $2.33 to $2.47. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU. |
Class A Common Stock
|
88 |
| 2025-06-23 | Leverone Jason A. |
Chief Financial Officer |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan. This transaction was executed in multiple trades at prices ranging from $2.33 to $2.47. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU. |
Class A Common Stock
|
303 |
| 2025-05-28 | Carruthers R Michael |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
100% of the shares subject to the option will vest on the earlier of May 28, 2026 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date. |
Stock Option (right to buy)
|
7,650 |
| 2025-05-28 | GREY MICHAEL G |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
100% of the shares subject to the option will vest on the earlier of May 28, 2026 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date. |
Stock Option (right to buy)
|
7,650 |
| 2025-05-28 | Mathers Edward T |
10% Owner |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
100% of the shares subject to the option will vest on the earlier of May 28, 2026 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date. |
Stock Option (right to buy)
|
7,650 |
| 2025-05-28 | Jansen Valerie Malyvanh |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
100% of the shares subject to the option will vest on the earlier of May 28, 2026 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date. |
Stock Option (right to buy)
|
7,650 |
| 2025-05-28 | Phillips Andrew John |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
100% of the shares subject to the option will vest on the earlier of May 28, 2026 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date. |
Stock Option (right to buy)
|
7,650 |
| 2025-05-28 | Manke Isaac |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
100% of the shares subject to the option will vest on the earlier of May 28, 2026 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date. |
Stock Option (right to buy)
|
7,650 |
| 2025-05-15 | ACORN BIOVENTURES, L.P. |
10% Owner |
Buy↑
Filing footnotes — Common Stock (Direct)
Shares held directly by Acorn Bioventures, L.P. ("Acorn"). Acorn Capital Advisors GP, LLC ("Acorn GP") is the general partner of Acorn. Anders Hove is the manager of Acorn GP. Each of Acorn GP and Mr. Hove disclaims beneficial ownership of disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. |
Common Stock
|
270,270 |
| 2025-05-15 | Cormorant Asset Management, LP |
Insider |
Sell↓
Filing footnotes — Class A Common Stock (Indirect)
Represents the weighted average sale price of Class A Common Stock (the "shares") sold in a series of open market transactions on the transaction date ranging from $1.85 to $2.03 per share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price. Cormorant Asset Management, LP serves as the investment manager to Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund III, LP ("Fund III"), Cormorant Private Healthcare Fund IV, LP ("Fund IV") and Cormorant Private Healthcare Fund V, LP ("Fund V"). Cormorant Global Healthcare GP, LLC, Cormorant Private Healthcare GP III, LLC, Cormorant Private Healthcare GP IV, LLC and Cormorant Private Healthcare GP V, LLC serve as the general partners of the Master Fund, Fund III, Fund IV and Fund V, respectively. Bihua Chen serves as the managing member of Cormorant Global Healthcare GP, LLC, Cormorant Private Healthcare GP III, LLC, Cormorant Private Healthcare GP IV, LLC and Cormorant Private Healthcare GP V, LLC, and the general partner of Cormorant Asset Management, LP. |
Class A Common Stock
(I)
|
1,813,439 |
| 2025-05-15 | ACORN BIOVENTURES, L.P. |
10% Owner |
Buy↑
Filing footnotes — Common Stock (Indirect)
Shares held directly by Acorn Bioventures 2, L.P. ("Acorn 2"). Acorn Capital Advisors GP 2, LLC ("Acorn GP 2") is the general partner of Acorn 2. Anders Hove is the manager of Acorn GP 2. Each of Acorn GP 2 and Mr. Hove disclaims beneficial ownership of disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. |
Common Stock
(I)
|
1,129,730 |
| 2025-05-12 | Cormorant Asset Management, LP |
Insider |
Sell↓
Filing footnotes — Class A Common Stock (Indirect)
Cormorant Asset Management, LP serves as the investment manager to Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund III, LP ("Fund III"), Cormorant Private Healthcare Fund IV, LP ("Fund IV") and Cormorant Private Healthcare Fund V, LP ("Fund V"). Cormorant Global Healthcare GP, LLC, Cormorant Private Healthcare GP III, LLC, Cormorant Private Healthcare GP IV, LLC and Cormorant Private Healthcare GP V, LLC serve as the general partners of the Master Fund, Fund III, Fund IV and Fund V, respectively. Bihua Chen serves as the managing member of Cormorant Global Healthcare GP, LLC, Cormorant Private Healthcare GP III, LLC, Cormorant Private Healthcare GP IV, LLC and Cormorant Private Healthcare GP V, LLC, and the general partner of Cormorant Asset Management, LP. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. Represents (i) 429,934 shares of Class A Common Stock beneficially owned by the Master Fund, (ii) 1,099,451 shares of Class A Common Stock beneficially owned by Fund III, (iii) 234,125 shares of Class A Common Stock beneficially owned by Fund IV, and (iv) 49,929 shares of Class A Common Stock beneficially owned by Fund V. |
Class A Common Stock
(I)
|
24,300 |
| 2025-04-07 | Leverone Jason A. |
Chief Financial Officer |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan. This transaction was executed in multiple trades at prices ranging from $2.57 to $3.03. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU. |
Class A Common Stock
|
1,844 |
| 2025-04-07 | Saccomano Nicholas A |
Director, President and CEO |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan. This transaction was executed in multiple trades at prices ranging from $2.57 to $3.03. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU. |
Class A Common Stock
|
516 |
| 2025-04-04 | Saccomano Nicholas A |
Director, President and CEO |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan. This transaction was executed in multiple trades at prices ranging from $3.10 to $3.58. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU. |
Class A Common Stock
|
358 |
| 2025-04-04 | Leverone Jason A. |
Chief Financial Officer |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan. This transaction was executed in multiple trades at prices ranging from $3.10 to $3.58. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU. |
Class A Common Stock
|
1,278 |
| 2025-03-31 | Mathers Edward T |
10% Owner |
Award↑
Filing footnotes — Class A Common Stock (Direct)
These securities are fully vested restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Class A Common Stock. The RSUs were granted to the Reporting Person in lieu of a quarterly cash retainer, at the election of the Reporting Person, under the Issuer's Outside Director Compensation Policy. |
Class A Common Stock
|
2,580 |
| 2025-03-31 | Manke Isaac |
Director |
Award↑
Filing footnotes — Class A Common Stock (Direct)
These securities are fully vested restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Class A Common Stock. The RSUs were granted to the Reporting Person in lieu of a quarterly cash retainer, at the election of the Reporting Person, under the Issuer's Outside Director Compensation Policy. |
Class A Common Stock
|
3,469 |
| 2025-01-27 | Leverone Jason A. |
Chief Financial Officer |
Award↑
Filing footnotes — Employee Stock Option (right to buy) (Direct)
1/48th of the shares subject to the option shall vest on February 27, 2025 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. |
Employee Stock Option (right to buy)
|
65,000 |
| 2025-01-27 | Hartley Dylan |
Chief Scientific Officer |
Award↑
Filing footnotes — Employee Stock Option (right to buy) (Direct)
1/48th of the shares subject to the option shall vest on February 27, 2025 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. |
Employee Stock Option (right to buy)
|
45,000 |
| 2025-01-27 | Agresta Samuel |
Chief Medical Officer |
Award↑
Filing footnotes — Employee Stock Option (right to buy) (Direct)
1/48th of the shares subject to the option shall vest on February 27, 2025 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. |
Employee Stock Option (right to buy)
|
45,000 |
| 2025-01-27 | Saccomano Nicholas A |
Director, President and CEO |
Award↑
Filing footnotes — Employee Stock Option (right to buy) (Direct)
1/48th of the shares subject to the option shall vest on February 27, 2025 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. |
Employee Stock Option (right to buy)
|
130,000 |
| 2024-10-07 | Leonard Braden Michael |
Insider |
Other↑
Filing footnotes — Common Stock (Direct)
Received in exchange for 1,020,769 shares of common stock of Reneo Pharmaceuticals. Pursuant to the Merger Agreement, on the Closing Date, Reneo effected a reverse stock split of Reneo's issued common stock at a ratio of 1:10. On October 4, 2024 (the "Closing Date"), Reneo Pharmaceuticals, Inc., a Delaware corporation and our predecessor company ("Reneo"), consummated the previously announced merger pursuant to the terms of the Agreement and Plan of Merger, dated as of May 10, 2024 (the "Merger Agreement"), by and among Reneo, Radiate Merger Sub I, Inc., a Delaware corporation and a direct, wholly-owned subsidiary of Reneo ("Merger Sub I"), Radiate Merger Sub II, LLC, a Delaware limited liability company and a direct, wholly-owned subsidiary of Reneo ("Merger Sub II"), and OnKure, Inc., a Delaware corporation ("Legacy OnKure"). |
Common Stock
|
102,076 |
| 2024-10-07 | Leonard Braden Michael |
Insider |
Other↑
Filing footnotes — Common Stock (Indirect)
Received in exchange for 3,457,395 shares of common stock of Reneo Pharmaceuticals. Pursuant to the Merger Agreement, on the Closing Date, Reneo effected a reverse stock split of Reneo's issued common stock at a ratio of 1:10. On October 4, 2024 (the "Closing Date"), Reneo Pharmaceuticals, Inc., a Delaware corporation and our predecessor company ("Reneo"), consummated the previously announced merger pursuant to the terms of the Agreement and Plan of Merger, dated as of May 10, 2024 (the "Merger Agreement"), by and among Reneo, Radiate Merger Sub I, Inc., a Delaware corporation and a direct, wholly-owned subsidiary of Reneo ("Merger Sub I"), Radiate Merger Sub II, LLC, a Delaware limited liability company and a direct, wholly-owned subsidiary of Reneo ("Merger Sub II"), and OnKure, Inc., a Delaware corporation ("Legacy OnKure"). BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. |
Common Stock
(I)
|
345,739 |